May/June 2013

The Affordable Care Act will help people access quality healthcare by capping their out-of-pocket costs. But some patients will face a significantly higher cap.

With new drugs in the pipeline and the impact of updated FDA drug safety policies on colchicine, gout may no longer be inexpensive to treat.

In this case study, the authors illustrate the diagnosis of institutional antibiotic resistance issues and drivers, and provide tailored recommendations for simultaneously reducing resistance, antibiotic costs, and treatment failure.

This analysis evaluates-from a US payer's perspective-the economic impact of using rivaroxaban versus enoxaparin for thromboprophylaxis following total hip or knee replacement surgery.

Changes in antidiabetic medication cost sharing due to a value-based pharmacy access program led to increased use of generic and brand antidiabetic oral medications and insulin.

To improve health and healthcare, we must begin to hold pharmacists accountable for quality.